TherapeuticsMD Inc (TXMD NASDAQ) stock market data APIs
$1.9902
-0.03(-1.5%)
as of July 9, 2026
Try our APIs with
free plan!
TherapeuticsMD Inc Financial Data Overview
Price chart is built with
Anychart
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Prev. Close
1.9902
Open
1.9619
High
2.0147
Low
1.9517
52 wk Range
0.99-2.95
Market Cap
22 801 K
P/E Ratio
197
Shares Outstanding
11 574 K
Revenue
3 353 K
EPS
0
Beta
0.588
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with TherapeuticsMD Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TherapeuticsMD Inc data using free add-ons & libraries
Get TherapeuticsMD Inc Fundamental Data
TherapeuticsMD Inc Fundamental data includes:
- Net Revenue: 3 353 K
- EBITDA: -1 407 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-18
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TherapeuticsMD Inc News
New
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
(RTTNews) - Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst...
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates
(RTTNews) - Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations....
FDA to remove “black box” warnings on hormone therapies for menopause
[FDA Headquarters - White Oak Campus] hapabapa Marking a pivotal moment in women’s health, the U.S. Food and Drug Administration (FDA) on Monday initiated actions to remove “black box” warnings...
TherapeuticsMD Q2 Earnings Summary
(RTTNews) - Below are the earnings highlights for TherapeuticsMD (TXMD): Earnings: $0.55 million in Q2 vs. -$1.05 million in the same period last year. EPS: $0.05 in Q2 vs. -$0.09 in the same period ...
Get TherapeuticsMD Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
